27566320|t|Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery
27566320|a|Recent clinical studies have documented the analgesic, anti-inflammatory, antioxidative and anxiolytic effects of exogenous melatonin. The pharmacokinetic properties of melatonin have primarily been investigated in experimental studies. The aim of this study was to estimate the pharmacokinetics of melatonin in patients undergoing surgery and general anesthesia. The study was designed as a prospective, two-phase cohort study. Patients were candidates for subpectoral breast augmentation surgery, and surgical procedures were performed by a single surgeon. The perioperative treatment protocol was standardized between patients. During the study, each patient received two separate oral administrations of melatonin 10 mg. Melatonin was administered 60 min before surgery, and at 9:00 p.m. the evening after surgery. The pharmacokinetic variables absorption half-life (t ½ absorption), time to maximal plasma concentration (T max), maximal plasma concentration (C max), elimination half-life (t ½ elimination), and area under the melatonin plasma concentration-time curve from time zero to infinity (AUC ∞) were estimated for both study phases. Median (interquartile range) values of t ½ absorption and T max were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively. C max values were significantly higher during surgery [5497.5 (2077.1-13,233.8) pg/ml] compared with postoperative values [2340.5 (1672.4-8871.4) pg/ml] (p = 0.005). Correspondingly, t ½ elimination was significantly extended during the postoperative phase [103.5 (57.8-237.8) min] compared with the perioperative phase [60.5 (47.8-83.6) min] (p = 0.015). AUC ∞ did not differ between the study phases (p > 0.05). These preliminary results indicate that postoperative melatonin dose should be augmented compared with preoperative administration if corresponding melatonin plasma levels are intended. Furthermore, postoperative administration times should be advanced compared with preoperative administration.
27566320	0	16	Pharmacokinetics	T039	C0031327
27566320	20	28	Repeated	T169	C0205341
27566320	29	38	Melatonin	T109,T121,T125	C0025219
27566320	39	59	Drug Administrations	T058	C3469597
27566320	60	68	Prior to	T079	C0332152
27566320	73	86	After Surgery	T079	C0032790
27566320	94	110	clinical studies	T062	C0008972
27566320	116	126	documented	T058	C1301725
27566320	131	140	analgesic	T033	C0948482
27566320	142	159	anti-inflammatory	T080	C1515999
27566320	161	174	antioxidative	T039	C3179302
27566320	179	197	anxiolytic effects	T039	C3179404
27566320	201	210	exogenous	T169	C0205228
27566320	211	220	melatonin	T109,T121,T125	C0025219
27566320	226	252	pharmacokinetic properties	T039	C0031327
27566320	256	265	melatonin	T109,T121,T125	C0025219
27566320	286	298	investigated	T169	C1292732
27566320	302	322	experimental studies	T062	C0681814
27566320	340	345	study	T062	C2603343
27566320	353	361	estimate	T081	C0750572
27566320	366	382	pharmacokinetics	T039	C0031327
27566320	386	395	melatonin	T109,T121,T125	C0025219
27566320	399	407	patients	T101	C0030705
27566320	419	426	surgery	T061	C0543467
27566320	431	449	general anesthesia	T061	C0002915
27566320	479	514	prospective, two-phase cohort study	T062	C1709709
27566320	516	524	Patients	T101	C0030705
27566320	545	556	subpectoral	T023	C0030747
27566320	557	584	breast augmentation surgery	T061	C0191925
27566320	590	609	surgical procedures	T061	C0543467
27566320	615	624	performed	T169	C0884358
27566320	630	636	single	T081	C0205171
27566320	637	644	surgeon	T097	C0582175
27566320	650	663	perioperative	T079	C1518988
27566320	664	682	treatment protocol	T061	C0040808
27566320	708	716	patients	T101	C0030705
27566320	729	734	study	T062	C2603343
27566320	741	748	patient	T101	C0030705
27566320	749	757	received	T080	C1514756
27566320	762	770	separate	T080	C0443299
27566320	771	791	oral administrations	T061	C0001563
27566320	795	810	melatonin 10 mg	T200	C1128362
27566320	812	821	Melatonin	T109,T121,T125	C0025219
27566320	826	838	administered	T058	C0806914
27566320	846	852	before	T079	C0332152
27566320	853	860	surgery	T061	C0543467
27566320	883	890	evening	T079	C0587117
27566320	891	904	after surgery	T079	C0032790
27566320	910	925	pharmacokinetic	T169	C0031328
27566320	926	935	variables	T169	C1521761
27566320	936	956	absorption half-life	T169	C1373172
27566320	958	972	t ½ absorption	T169	C1373172
27566320	975	1011	time to maximal plasma concentration	T081	C2348796
27566320	1013	1018	T max	T081	C2348796
27566320	1021	1049	maximal plasma concentration	T081	C2347813
27566320	1051	1056	C max	T081	C2347813
27566320	1059	1080	elimination half-life	T081	C2348397
27566320	1082	1097	t ½ elimination	T081	C2348397
27566320	1104	1187	area under the melatonin plasma concentration-time curve from time zero to infinity	T081	C2827912
27566320	1189	1194	AUC ∞	T081	C2827912
27566320	1201	1210	estimated	T081	C0750572
27566320	1220	1225	study	T062	C2603343
27566320	1226	1232	phases	T079	C0205390
27566320	1234	1240	Median	T081	C0876920
27566320	1242	1261	interquartile range	T081	C1711350
27566320	1273	1287	t ½ absorption	T169	C1373172
27566320	1292	1297	T max	T081	C2348796
27566320	1303	1316	significantly	T078	C0750502
27566320	1317	1326	increased	T081	C0205217
27566320	1338	1357	postoperative phase	T079	C0032790
27566320	1403	1411	compared	T052	C1707455
27566320	1417	1432	perioperatively	T079	C1518988
27566320	1514	1526	C max values	T081	C2347813
27566320	1532	1545	significantly	T078	C0750502
27566320	1546	1552	higher	T080	C0205250
27566320	1560	1567	surgery	T061	C0543467
27566320	1601	1609	compared	T052	C1707455
27566320	1615	1628	postoperative	T079	C0032790
27566320	1629	1635	values	T081	C1522609
27566320	1697	1712	t ½ elimination	T081	C2348397
27566320	1717	1730	significantly	T078	C0750502
27566320	1731	1739	extended	T169	C0231448
27566320	1751	1770	postoperative phase	T079	C0032790
27566320	1796	1804	compared	T052	C1707455
27566320	1814	1833	perioperative phase	T079	C2712230
27566320	1870	1875	AUC ∞	T081	C2827912
27566320	1880	1890	not differ	T033	C3842396
27566320	1903	1908	study	T062	C2603343
27566320	1909	1915	phases	T079	C0205390
27566320	1934	1945	preliminary	T079	C0439611
27566320	1946	1953	results	T169	C1274040
27566320	1968	1981	postoperative	T079	C0032790
27566320	1982	1991	melatonin	T109,T121,T125	C0025219
27566320	1992	1996	dose	T081	C0178602
27566320	2007	2016	augmented	T081	C0205217
27566320	2017	2025	compared	T052	C1707455
27566320	2031	2043	preoperative	T079	C0445204
27566320	2044	2058	administration	T058	C3469597
27566320	2076	2085	melatonin	T109,T121,T125	C0025219
27566320	2086	2092	plasma	T031	C0032105
27566320	2093	2099	levels	T080	C0441889
27566320	2104	2112	intended	T080	C1283828
27566320	2127	2140	postoperative	T079	C0032790
27566320	2141	2155	administration	T058	C3469597
27566320	2156	2161	times	T079	C0040223
27566320	2172	2180	advanced	T080	C0205179
27566320	2181	2189	compared	T052	C1707455
27566320	2195	2207	preoperative	T079	C0445204
27566320	2208	2222	administration	T058	C3469597